Interestingly, PIK3CA-mutant ER+ breast cancers display minimal AKT activation and little dependence on AKT signaling compared to tumors with other PI3K pathway alterations, such as PTEN loss4,12. This evidence concerns the gene ESR1 and breast cancer.